Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 17, 2016

Nevro’s new surgical leads for spinal cord stimulation system secures FDA approval

The US Food and Drug Administration (FDA) has granted approval to medical device firm Nevro’s surgical leads, designed to be used with the Senza Spinal Cord Stimulation (SCS) System delivering HF10 Therapy.

The US Food and Drug Administration (FDA) has granted approval to medical device firm Nevro’s surgical leads, designed to be used with the Senza Spinal Cord Stimulation (SCS) System delivering HF10 Therapy.

The Senza system is claimed being the only SCS system, an evidence-based neuromodulation platform that delivers Nevro’s patented HF10 therapy, which is an SCS therapy issuing electrical pulses to the spinal cord to decrease pain.

The electrical pulses are delivered by small electrodes on leads, which are placed at the vicinity of the spinal cord and connected to a compact, battery-powered generator implanted under the skin.

HF10 therapy is the only SCS therapy indicated to provide pain relief without paresthesia, and comparative pivotal study has proved that HF10 is the first such SCS therapy to exhibit better results when compared to the existing SCS for back and leg pain.

" … With the ability to use surgical leads with the Senza SCS system, I look forward to providing Nevro’s therapy to a broader set of patients."

Paresthesia is a stimulation-induced sensation, such as tingling or buzzing, which is the basis of traditional SCS.

Thomas Jefferson University Neurosurgery professor and programme director Dr Ashwini Sharan said: "In my practice, I have already witnessed the significant advantages of HF10 therapy, which provides superior pain relief for chronic back and leg pain patients.

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

"Now, with the ability to use surgical leads with the Senza SCS system, I look forward to providing Nevro’s therapy to a broader set of patients."

Nevro’s innovations in SCS, including the Senza system and HF10 therapy, are utilised by more than 85 issued US and international patents.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU